Preclinical studies of glimepiride

Drugs of Today

Volumn 34, Issue 5, 1998, Pages 391-400

  Nguyen, Chi ^a   Pan, Jianqiu ^a   Arthur, M Charles ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HYPOGLYCEMIA; IMMUNOMODULATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 0031810229     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.5.472189     Document Type: Review

References (46)

1. White, J.R. Jr. The pharmacologic management of patients with type II diabetes mellitus in the era of new oral agents and insulin analogs. Diabetes Spectrum 1996, 9: 227-34.
2. Melander, A. Clinical pharmacology of suffonylureas. Metabolism 1987, 36: 12-6.
3. Lazdunski, M. Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 1996, 28: 448-95.
4. Ashcroft, F.M. Mechanisms of the glycaemic effects of sulfonytureas. Horm Metab Res 1996, 28: 456-63.
5. Charles, M.A., Lawecki, J., Grodsky, G.M. Cyclic nucleotides in pancreatic islets. Tolbutamide and arginine induced insulin release. Diabetes 1976, 25: 256.
6. Kraemer, W., Müller, G., Geisen, K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at ß-cells. Horm Metab Res 1996, 28: 464-8.
7. + channels. Diabetes Res Clin Pract 1995, 28(Suppl.): S67-80.
8. Draeger, E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995, 28(Suppl.): S139-46.
9. Schwanstecher, M., Manner, K., Panten, U. Inhibition of potassium channel and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets. Pharmacology 1995, 49: 105-11.
10. Müller, G., Satoh, Y., Geisen, K. Extrapancreatic effects of sulfonylurea: A comparison between glimepiride and conventional sulfonylurea. Diabetes Res Clin Pract 1995, 28(Suppl.): S115-37.
11. Müller, G., Geisen, K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 1996, 28: 469-87.
12. Takeda, Y. et al. Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse. Eur J Pharmacol 1996, 308: 205-10.
13. Sato, J., Oshawa I., Oshida, Y. et al. Effects of glimepiride on in vitro insulin action in normal and diabetic rats. Diabetes Res Clin Pract 1993, 22: 309.
14. Müller, G., Wied, S., Wetekam, E.-M. et al. Stimulation of glucose utilization 3T3 adipocytes and rat diaphragm in vitro by the sulfonylurea, glimepiride and glibenclamide, in correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 1994, 48: 985-96.
15. Müller, G., Wied, S. The sulfonylurea drug, glimepiride, stimulate glucose transport, glucose transporter translocation, and dephosphorylation in insulin resistant rat adipocytes in vitro. Diabetes 1993, 42: 1852-67.
16. Shielman, R.G., Bloch, G.D., Rothman, L. In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Proc Natl Acad Sci USA 1995, 92: 8535-42.
17. Pulido, N., Casla, A., Suarez, A., Casarova, B., Anieta, F.J., Rovira, A. Sulfonylurea stimulates glucose uptake in rats through an ATP-sensitive potassium channel dependent mechanism. Diabetelogia 1996, 39: 22-7.
18. Ohsawa, I., Sato, J., Oshida, Y., Saksmoto, N., Sato, Y. The acute and chronic effects of glimepiride on insulin sensitivity and responsiveness in rats. Diabetes 1991, 40(Suppl.): Abst 1364.
19. Kawamori, R. et al. Influence of oral sulfonylurea agents on hepatic glucose uptake. Diabetes Res Clin Pract 1995, 28(Suppl.): S109-13.
20. Massi-Benedetti, M., Herz, M., Pleiffer, C. The effects of acute exercise on metabolic control on type 11 diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996, 28: 451-5.
21. Végh, A., Papp, J.G. Haemodynamic and other effects of sulfonylurea drugs on the hearts. Diabetes Res Clin Pract 1995, 31(Suppl.): S43-53.
22. Giesen, K., Vegh, A., Krause, E., Papp, J.G. Sulfonylurea and cardiovascular effects. Horm Metab Res 1996, 28: 496-507.
23. ATP currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim. Pfl̈gers Arch 1995, 429: 625-35.
24. Ballagi-Pódany, G., Pogátsa, G., Koltai, M.Z. et al. Effect of glimepiride on the electrical activity of isolated rabbit heart muscle. Arzneim-Forsch/Drug Res 1992, 42: 111-3.
25. ATP channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dogs. J Clin Invest 1992, 89: 2071-4.
26. Pogätsa, G. Potassium channels in the cardiovascular system. Diabetes Res Clin Pract 1995, 28(Suppl.): S91-8.
27. Pogátsa, G. What kind of cardiomuscular alterations could be influenced positively by oral antidiabetic agents? Diabetes Res Clin Pract 1996, 31(Suppl.): S27-31.
28. Eckel, J. Direct effects of glimepiride in protein expression of cardiac glucose transporters. Horm Metab Res 1995, 28: 508-11.
29. Eckel, J., Müller, G., Bahr, M. Sulfonylurea effects on cardiac glucose transport. J Clin Endocrinol Metab 1995, 136: 2547-53.
30. Garvey, W.T., Hardin, D., Hushaszova, M., Dominiguez, J.H. Effects of diabetes on myocardial glucose transport system in rat:Implications for diabetic cardiomyopathy. Am J Physiol 1993, 264: H837-44.
31. Pogátsa, G., Koltai, M.Z., Ballagi-Pordany, G. Influence of hypoglycemic sulfonylurea composed on the incidence of ventricular ectopic beats in NIDDM patients treated with digitalis. Curr Ther Res Clin Exp 1993, 53: 329-39.
32. Pogätsa, G., Koltai, M.Z., Jeremendy, G. et al. The effect of sulfonylurea therapy on the out-come of coronary heart diseases in diabetic patient. Acta Med Hung 1995, 49: 39-51.
33. Bijlstra, P.J., Lutterman, J.A.M., Russel, F.G., Thien, T., Smits, P. Interaction of sulfonylureas derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996, 39: 1083-90.
34. Qi, R. et al. Sulfonylureas inhibit arachidonic acid-induced platelet activation. Biochem Pharmacol 1995, 49: 1735-9.
35. Zhang, H., Cooke, D. Antagonism of eicosanoid-induced contraction of rat aorta by sulfonylurea. Pharmacology 1994, 49: 173-83.
36. Williams, A.J.K., Beales, P.E., Krug, J. et al. Tolbutamide reduces the incidence of diabetes in the non-obese diabetic (NOD) mouse. Diabetolgia 1993, 36: 487-92.
37. Hosszufalusi, N., Reinherz, L., Takei, S., Chan, E., Charles, M.A. Glipizide-induced prevention of diabetes and autoimmune events in the BB rat. J Autoimmun 1994, 7: 753-61.
38. Cheta, D.M.J.L., Chan, E., Kunakorn, T., Charles, M.A. Glimepiride-induced prevention of diabetes and autoimmune events in the BB rat. Life Sci 1995, 57: 2281-90.
39. Pan, J., Chan, E., Cheta, D., Schranz, V., Charles, M.A. The effects of nicotinamide and glimepiride on diabetes prevention in BB rats, Life Sci 1995, 57: 1525-32.
40. Nagy, M., Chan, E., Charles, M.A. Glipizide-induced immunomodulation: Inhibition of human mononuclear cell stimulation and macrophage mediated islet cell killing in the BB rat. Metabolism 1992, 41: 420-5.
41. Teruya, M., Takei, S., Forrest, L., Grunewald, A., Chan, E., Charles, M.A. Pancreatic islet function in non-diabetic and diabetic BB rats. Diabetes 1993, 42: 1310-7.
42. Selam, J.-L., Woertz, L., Lozano, J., Robinson, M., Chan, E., Charles, M.A. The use of glipszide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes. Autoimmunity 1993, 16: 281-8.
43. Formby, B., Hosszufalusi, N., Chan, E. et al. Quantitative and functional analyses of spleen and in situ islet immune cells before and after diabetes onset in the NOD mouse. Autoimmunity 1992, 12: 95-102.
44. Hosszufalusi, N., Chan, E., Teruya, M., Takei, S., Granger, G., Charles, M.A. Quantitative phenotypic and functional analyses of islet immune cells before and after diabetes onset in the BB rat. Diabetologia 1993, 36: 1146-54.
45. + channel expression in double-negative CD4-CD8-T cells. Eur J Immunol 1990, 20: 747-51.
46. Pan, J., Chan, E., Yu, E., Chen, J., Schranz, V., Charles, M.A. Prevention and cure of type 1 diabetes in the BB rat by islet allotransplantation and glimepiride treatment. Transplant Proc 1995, 27: 1394.